Drugs / bivalent subtype C gp120/MF59
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02404311 Comparator | Feb 2015 → Aug 2018 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bivalent subtype C gp120/MF59 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02404311 ↗ |
| Known as | bivalent gp120/MF59 | “The study uses 2 different vaccines: ALVAC-HIV (vCP2438) and bivalent gp120/MF59.” NCT02404311 ↗ |
| Modality | Vaccine | “The Protein vaccine has man-made pieces of a protein found on the outside of HIV.” NCT02404311 ↗ |
| Route | Intramuscular | “delivered as a 0.5 mL IM injection” NCT02404311 ↗ |